Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 25

Results For "patients"

2956 News Found

Equillium and Biocon announce positive data from Phase 2 study evaluating Itolizumab for ulcerative colitis
Diagnostic Center | February 07, 2025

Equillium and Biocon announce positive data from Phase 2 study evaluating Itolizumab for ulcerative colitis

Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo


P. D. Hinduja Hospital spreads solidarity for cancer awareness
Healthcare | February 07, 2025

P. D. Hinduja Hospital spreads solidarity for cancer awareness

Cancer cases in India estimated to reach 1.57 million in 2025


Tata Chemicals signs MoU with BSDT’s Integrated Cancer Treatment and Research Centre, Pune
Healthcare | February 07, 2025

Tata Chemicals signs MoU with BSDT’s Integrated Cancer Treatment and Research Centre, Pune

This collaboration aims to bridge modern scientific research with traditional Ayurvedic wisdom, fostering innovative solutions that support holistic well-being


Philogen completes patient enrollment of Phase III FIBROSARC trial in Soft Tissue Sarcoma
News | February 06, 2025

Philogen completes patient enrollment of Phase III FIBROSARC trial in Soft Tissue Sarcoma

These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential


Alkem launches Kojiglo serum to manage facial hyperpigmentation
News | February 05, 2025

Alkem launches Kojiglo serum to manage facial hyperpigmentation

This innovative formulation combines cutting-edge ingredients is a first of its kind in India to have a Duo-Lipo technology


Pfizer reports 2024 revenues 7% higher at $63.6 billion
News | February 05, 2025

Pfizer reports 2024 revenues 7% higher at $63.6 billion

Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion


FDA approves Roche’s Susvimo as the first and only continuous delivery treatment diabetes-related blindness
Drug Approval | February 05, 2025

FDA approves Roche’s Susvimo as the first and only continuous delivery treatment diabetes-related blindness

Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)


Akums combines two potent diabetes medicines for enhanced treatment efficacy
News | February 04, 2025

Akums combines two potent diabetes medicines for enhanced treatment efficacy

Akums Drugs & Pharmaceuticals has launched Dapagliflozin + Pioglitazone tablets, a dual-action therapy for diabetes management


Lupin announces closure of USFDA inspection at its Somerset facility with zero 483 observations
Drug Approval | February 03, 2025

Lupin announces closure of USFDA inspection at its Somerset facility with zero 483 observations

The inspection was carried out from January 28 to February 1, 2025


CuraTeQ Biologics receives positive opinion for biosimilar Dyrupeg from EMA
News | February 03, 2025

CuraTeQ Biologics receives positive opinion for biosimilar Dyrupeg from EMA

Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia